Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.

被引：12
|
作者：
Garcia-Manero, Guillermo
Daver, Naval Guastad
Xu, Jin
Chao, Mark
Chung, Trisha
Tan, Anderson
Wang, Vivian
Wei, Andrew
Vyas, Paresh
Sallman, David Andrew
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[3] Alfred Hosp, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Univ Oxford, MRC Mol Haematol Unit, Oxford, England
[6] Univ Oxford, Oxford Biomed Res Ctr, Oxford, England
[7] Oxford Univ Hosp, Oxford, England
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7055
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S343 - S344
  • [2] Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher Risk Myelodysplastic Syndrome: The Phase 3, Randomized, ENHANCE Study
    Garcia-Manero, Guillermo
    Daver, Naval
    Xu, Jin
    Chao, Mark
    Chung, Trisha
    Tan, Anderson
    Wang, Yan
    Wei, Andrew
    Vyas, Paresh
    Sallman, David
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 : S3 - S3
  • [3] Impact of Mutational Landscape and CD47 Levels in the Magrolimab plus Azacitidine Vs Placebo plus Azacitidine Trial in Patients with Untreated Higher Risk Myelodysplastic Syndrome
    Johnson, Lisa D. S.
    Zhang, Yajia
    BLOOD, 2024, 144 : 4604 - 4605
  • [4] Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib plus Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
    Garcia-Manero, Guillermo
    Navada, Shyamala C.
    Fenaux, Pierre
    Zbyszewski, Patrick S.
    Adesanya, Afoluso Ronnee
    Azarnia, Nozar
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [5] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 2119 - 2124
  • [6] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Sekeres, Mikkael A.
    Watts, Justin
    Radinoff, Atanas
    Sangerman, Montserrat Arnan
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua F.
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Ades, Lionel
    LEUKEMIA, 2021, 35 (07) : 2119 - 2124
  • [7] Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
    Sallman, David
    Al Malki, Monzr
    Asch, Adam
    Wang, Eunice
    Jurcic, Joseph
    Bradley, Terrence
    Flinn, Ian
    Pollyea, Daniel
    Kambhampati, Suman
    Tanaka, Tiffany
    Zeidner, Joshua
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Lal, Indu
    Vyas, Paresh
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S314 - S315
  • [8] Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS).
    Chen, James Yuhtyng
    Johnson, Lisa
    McKenna, Kelly Marie
    Choi, Timothy S.
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan M.
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris H. M.
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 3637 - 3637
  • [10] Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
    Sallman, David Andrew
    Al Malki, Monzr M.
    Asch, Adam Steven
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel Aaron
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Gu, Lin
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol Elaine
    Lal, Indu
    Vyas, Paresh
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345